First trial of mAb targeting anti-Müllerian human receptor II tested in oncology patients
Initial results expected in 2017
BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners, led the round; the funds raised will finance clinical trials for GM102, a therapeutic antibody targeting gynecological cancers
GamaMabs Pharma will present new results from its collaboration with the Institut Curie at TAT meeting (Paris, March 2-4 2015) with a poster describing 3C23K antibody efficacy in combination with chemotherapy in PDX models.
Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer.
GamaMabs Pharma and Mayo Clinic will collaborate on a study on the efficacy of GamaMabs’ 3C23K antibody in ovarian patient-derived xenografts (PDX) models
Two studies on AMHR2 project were accepted for a publication in mAbs journal and a poster by Institut Curie (Paris, France) at the 10th Biennial Ovarian Cancer Research Symposium (Seattle, 8-9 September 2014)
Alto Invest joins GamaMabs investors with a €0.5m equity financing and Bpifrance awards a €0.6m reimbursable aid for the development of 3C23K program in ovarian cancer.